{"id":"keytruda-injectable-product","safety":{"commonSideEffects":[{"rate":"3-4%","effect":"Pneumonitis"},{"rate":"4-6%","effect":"Hypothyroidism"},{"rate":"5-7%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL2094006","moleculeType":"Small molecule","molecularWeight":"702.93"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Keytruda works by inhibiting the PD-1 receptor on T cells, allowing them to recognize and attack cancer cells.","oneSentence":"PD-1 inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:58:04.341Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Melanoma"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT06524544","phase":"PHASE3","title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-12-02","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":320},{"nctId":"NCT04645602","phase":"EARLY_PHASE1","title":"Merck IIT: RRP Pembro and Lenvatinib","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-07-18","conditions":"Human Papilloma Virus, Recurrent Respiratory Papillomatosis, Pulmonary Disease","enrollment":20},{"nctId":"NCT06385080","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-22","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":287},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT07455019","phase":"PHASE2","title":"A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-05-01","conditions":"Esophageal Cancer","enrollment":28},{"nctId":"NCT03969446","phase":"PHASE1","title":"Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-05-04","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia","enrollment":54},{"nctId":"NCT05977907","phase":"PHASE2","title":"Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-12-14","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT07431827","phase":"PHASE3","title":"MK-3475A±MK-1084 in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-04-01","conditions":"Non-small Cell Lung Cancer","enrollment":400},{"nctId":"NCT05081609","phase":"PHASE1, PHASE2","title":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascendis Pharma Oncology Division A/S","startDate":"2022-01-11","conditions":"Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":320},{"nctId":"NCT04752826","phase":"PHASE1, PHASE2","title":"BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)","status":"RECRUITING","sponsor":"BioInvent International AB","startDate":"2021-01-25","conditions":"Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma","enrollment":176},{"nctId":"NCT07300475","phase":"PHASE1","title":"Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-03-31","conditions":"Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT07326137","phase":"","title":"A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-26","conditions":"Advanced Biliary Tract Cancer(BTC), Advanced Pancreatic Cancers, Cancer-related Pain","enrollment":103},{"nctId":"NCT04266730","phase":"PHASE1","title":"Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-02-22","conditions":"Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck","enrollment":6},{"nctId":"NCT05816252","phase":"PHASE2","title":"A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Klus Pharma Inc.","startDate":"2023-04-19","conditions":"Non-small Cell Lung Cancer","enrollment":356},{"nctId":"NCT04995003","phase":"PHASE1","title":"HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2021-12-07","conditions":"Sarcoma, HER-2 Protein Overexpression, Osteosarcoma","enrollment":25},{"nctId":"NCT03228667","phase":"PHASE2","title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-12-11","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma","enrollment":40},{"nctId":"NCT04616248","phase":"PHASE1","title":"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2023-01-09","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8","enrollment":14},{"nctId":"NCT05307874","phase":"PHASE1, PHASE2","title":"Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"ImCheck Therapeutics","startDate":"2022-05-04","conditions":"Solid Tumor, Adult","enrollment":56},{"nctId":"NCT05106127","phase":"PHASE2","title":"Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem","status":"NOT_YET_RECRUITING","sponsor":"Evergreen Therapeutics, Inc.","startDate":"2026-08","conditions":"Advanced Endometrial Cancer","enrollment":28},{"nctId":"NCT05077215","phase":"PHASE3","title":"Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Evergreen Therapeutics, Inc.","startDate":"2026-12","conditions":"Advanced Endometrial Cancer","enrollment":450},{"nctId":"NCT03007732","phase":"PHASE2","title":"Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT","status":"COMPLETED","sponsor":"David Oh","startDate":"2017-05-17","conditions":"Prostatic Neoplasms","enrollment":23},{"nctId":"NCT06400160","phase":"PHASE1, PHASE2","title":"Clinical Trial of TB511 in Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Twinpig Biolab, Inc.","startDate":"2026-03","conditions":"NSCLC, Prostate Cancer, Colorectal Cancer","enrollment":12},{"nctId":"NCT05901285","phase":"PHASE1","title":"Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Vaxiion Therapeutics","startDate":"2023-11-02","conditions":"Advanced Solid Tumor, Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab","enrollment":43},{"nctId":"NCT04725331","phase":"PHASE1, PHASE2","title":"A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors","status":"TERMINATED","sponsor":"Transgene","startDate":"2021-02-25","conditions":"Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma","enrollment":31},{"nctId":"NCT06078384","phase":"PHASE2","title":"Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-12-27","conditions":"Triple-negative Breast Cancer","enrollment":354},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT04370587","phase":"PHASE1, PHASE2","title":"A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"ImmVira Pharma Co. Ltd","startDate":"2020-09-17","conditions":"Solid Tumor, Melanoma, HNSCC","enrollment":30},{"nctId":"NCT03275506","phase":"PHASE2","title":"PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2018-02-26","conditions":"Ovarian Cancer Stage IV","enrollment":91},{"nctId":"NCT05492682","phase":"PHASE1","title":"START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Valo Therapeutics Oy","startDate":"2023-02-02","conditions":"Melanoma (Skin), Triple-Negative Breast Cancer, Non-Small Cell Lung Cancer","enrollment":15},{"nctId":"NCT06767800","phase":"PHASE2","title":"A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2024-11-21","conditions":"Gastroesophageal Adenocarcinoma","enrollment":204},{"nctId":"NCT05894889","phase":"PHASE2","title":"Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University","startDate":"2024-01-30","conditions":"Stage IIIB(N2) Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer","enrollment":70},{"nctId":"NCT07054086","phase":"","title":"Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-03-01","conditions":"Esophageal Cancer","enrollment":30},{"nctId":"NCT06646445","phase":"PHASE2","title":"Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.","status":"NOT_YET_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2025-09","conditions":"Colon Cancer","enrollment":60},{"nctId":"NCT03970746","phase":"PHASE1, PHASE2","title":"Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"PDC*line Pharma SAS","startDate":"2019-09-10","conditions":"Non Small Cell Lung Cancer","enrollment":73},{"nctId":"NCT03432741","phase":"PHASE1","title":"Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2018-03-27","conditions":"Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma","enrollment":17},{"nctId":"NCT06949761","phase":"PHASE1, PHASE2","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-06","conditions":"Solid Tumor","enrollment":240},{"nctId":"NCT03983668","phase":"PHASE1, PHASE2","title":"CMP-001 for Relapsed and Refractory Lymphoma","status":"COMPLETED","sponsor":"Umar Farooq","startDate":"2020-01-31","conditions":"Lymphoma","enrollment":14},{"nctId":"NCT03954067","phase":"PHASE1","title":"A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2019-09-03","conditions":"Metastatic Cancer, Solid Tumors, Advanced Cancer","enrollment":72},{"nctId":"NCT06099782","phase":"PHASE2","title":"A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-26","conditions":"Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma","enrollment":147},{"nctId":"NCT06920810","phase":"PHASE4","title":"Viscum Album for TNBC on Adjuvant Pembrolizumab","status":"RECRUITING","sponsor":"Ilsan Cha hospital","startDate":"2025-03-19","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":40},{"nctId":"NCT05438329","phase":"PHASE1, PHASE2","title":"First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"DualityBio Inc.","startDate":"2022-07-19","conditions":"Advanced Solid Tumor","enrollment":1123},{"nctId":"NCT03058289","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6","status":"COMPLETED","sponsor":"Intensity Therapeutics, Inc.","startDate":"2017-02-09","conditions":"Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma","enrollment":111},{"nctId":"NCT06691594","phase":"PHASE2","title":"Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-02","conditions":"Breast Cancer Invasive","enrollment":20},{"nctId":"NCT06366451","phase":"EARLY_PHASE1","title":"PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC","status":"RECRUITING","sponsor":"Presage Biosciences","startDate":"2024-05-22","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":15},{"nctId":"NCT03153410","phase":"EARLY_PHASE1","title":"Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-09-27","conditions":"Pancreatic Cancer","enrollment":11},{"nctId":"NCT04068181","phase":"PHASE2","title":"Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).","status":"COMPLETED","sponsor":"Amgen","startDate":"2020-01-22","conditions":"Melanoma","enrollment":72},{"nctId":"NCT05877430","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer","status":"RECRUITING","sponsor":"CJ Bioscience, Inc.","startDate":"2023-09-11","conditions":"NSCLC, HNSCC, Melanoma","enrollment":160},{"nctId":"NCT03134456","phase":"PHASE4","title":"Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2018-05-14","conditions":"Metastatic Non-Small Cell Lung Carcinoma","enrollment":50},{"nctId":"NCT05824975","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","status":"RECRUITING","sponsor":"GI Innovation, Inc.","startDate":"2023-05-30","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)","enrollment":358},{"nctId":"NCT06111196","phase":"PHASE1","title":"Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2023-11-05","conditions":"Healthy Male Subjects","enrollment":59},{"nctId":"NCT06284590","phase":"PHASE2","title":"Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients","status":"RECRUITING","sponsor":"Philogen S.p.A.","startDate":"2024-07-12","conditions":"Melanoma Stage III, Melanoma Stage IV","enrollment":162},{"nctId":"NCT06643910","phase":"NA","title":"A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"BioSyngen Pte Ltd","startDate":"2024-10-24","conditions":"Non-small Cell Lung Cancer","enrollment":12},{"nctId":"NCT03996473","phase":"PHASE1","title":"Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases","status":"TERMINATED","sponsor":"Bayer","startDate":"2020-03-06","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":8},{"nctId":"NCT04387461","phase":"PHASE2","title":"Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin","status":"COMPLETED","sponsor":"CG Oncology, Inc.","startDate":"2020-12-08","conditions":"Non Muscle Invasive Bladder Cancer","enrollment":35},{"nctId":"NCT03447314","phase":"PHASE1","title":"Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-26","conditions":"Neoplasms","enrollment":54},{"nctId":"NCT02826486","phase":"PHASE2","title":"Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2016-09","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":80},{"nctId":"NCT04770207","phase":"PHASE2","title":"Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2020-11-01","conditions":"Hepatocellular Carcinoma, Solid Tumor, Adult","enrollment":100},{"nctId":"NCT02509507","phase":"PHASE1, PHASE2","title":"Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-02-05","conditions":"Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node","enrollment":127},{"nctId":"NCT05077709","phase":"PHASE2","title":"IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"IO Biotech","startDate":"2022-02-14","conditions":"Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder","enrollment":63},{"nctId":"NCT04739618","phase":"PHASE2","title":"Metastatic Solid Cancer Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunSYS, LLC","startDate":"2021-03-04","conditions":"Metastatic Cancer","enrollment":32},{"nctId":"NCT03755739","phase":"PHASE2, PHASE3","title":"Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2018-11-01","conditions":"Hepatocarcinoma, Lung Cancer, Melanoma","enrollment":200},{"nctId":"NCT03921021","phase":"PHASE2","title":"Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2019-05-09","conditions":"Esophagogastric Adenocarcinoma","enrollment":17},{"nctId":"NCT06045767","phase":"PHASE2","title":"T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ari Raphael","startDate":"2024-06","conditions":"Non-small Cell Lung Cancer Metastatic","enrollment":30},{"nctId":"NCT06413095","phase":"EARLY_PHASE1","title":"PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS","status":"COMPLETED","sponsor":"Presage Biosciences","startDate":"2022-06-01","conditions":"Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma","enrollment":13},{"nctId":"NCT04713371","phase":"PHASE2","title":"A Phase 2 Trial for Patients With Metastatic Solid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rampart Health, L.L.C.","startDate":"2021-05-19","conditions":"Metastatic Cancer","enrollment":32},{"nctId":"NCT04541108","phase":"EARLY_PHASE1","title":"Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies","status":"RECRUITING","sponsor":"Presage Biosciences","startDate":"2021-07-26","conditions":"Solid Tumor","enrollment":15},{"nctId":"NCT03639948","phase":"PHASE2","title":"Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2018-09-04","conditions":"Triple-negative Breast Cancer","enrollment":120},{"nctId":"NCT04510636","phase":"PHASE2","title":"Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-12-20","conditions":"Classical Hodgkin Lymphoma, Relapsed Cancer, Refractory Cancer","enrollment":37},{"nctId":"NCT06320353","phase":"PHASE3","title":"Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm","startDate":"2023-09-27","conditions":"Skin Melanoma","enrollment":266},{"nctId":"NCT06307093","phase":"PHASE1","title":"Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm","startDate":"2023-03-01","conditions":"Skin Melanoma, Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma","enrollment":90},{"nctId":"NCT03861793","phase":"PHASE1, PHASE2","title":"A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)","status":"COMPLETED","sponsor":"Mural Oncology, Inc","startDate":"2019-02-26","conditions":"Advanced Solid Tumors","enrollment":116},{"nctId":"NCT06276504","phase":"PHASE2, PHASE3","title":"Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-04","conditions":"Progressive Multifocal Leukoencephalopathy","enrollment":33},{"nctId":"NCT06022757","phase":"PHASE1, PHASE2","title":"Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)","status":"RECRUITING","sponsor":"Evopoint Biosciences Inc.","startDate":"2023-09-20","conditions":"Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma","enrollment":204},{"nctId":"NCT03789097","phase":"PHASE1, PHASE2","title":"Vaccination With Flt3L, Radiation, and Poly-ICLC","status":"UNKNOWN","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-04-05","conditions":"Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma","enrollment":56},{"nctId":"NCT05096390","phase":"PHASE2","title":"Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2022-06-01","conditions":"Papillary Renal Cell Carcinoma Type 2","enrollment":72},{"nctId":"NCT06194695","phase":"","title":"DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Ze-yang Ding, MD","startDate":"2022-02-01","conditions":"Cholangiocarcinoma Non-resectable","enrollment":100},{"nctId":"NCT04294576","phase":"PHASE1","title":"Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors","status":"UNKNOWN","sponsor":"BJ Bioscience, Inc.","startDate":"2019-12-04","conditions":"Locally Advanced/Metastatic Solid Tumors","enrollment":92},{"nctId":"NCT05509985","phase":"PHASE1","title":"A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"AskGene Pharma, Inc.","startDate":"2023-08-09","conditions":"Advanced Solid Tumors","enrollment":100},{"nctId":"NCT04703426","phase":"PHASE2","title":"Sargramostim (GM-CSF) + PD-1","status":"WITHDRAWN","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-04-16","conditions":"Unresectable Melanoma, Metastatic Melanoma, Stage III Melanoma","enrollment":""},{"nctId":"NCT02376699","phase":"PHASE1","title":"Safety Study of SEA-CD40 in Cancer Patients","status":"TERMINATED","sponsor":"Seagen Inc.","startDate":"2015-02-28","conditions":"Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease","enrollment":159},{"nctId":"NCT05809336","phase":"PHASE2, PHASE3","title":"Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2019-05-01","conditions":"Advanced Solid Tumor","enrollment":172},{"nctId":"NCT03193931","phase":"PHASE2","title":"Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers","status":"TERMINATED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-02-02","conditions":"Cancer of Head and Neck","enrollment":47},{"nctId":"NCT05386056","phase":"PHASE2","title":"Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Peking University","startDate":"2022-12-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":54},{"nctId":"NCT02263508","phase":"PHASE3","title":"Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma","status":"TERMINATED","sponsor":"Amgen","startDate":"2014-12-08","conditions":"Melanoma","enrollment":713},{"nctId":"NCT04571632","phase":"PHASE2","title":"Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2020-09-22","conditions":"Non Small Cell Lung Cancer, Solid Tumor","enrollment":36},{"nctId":"NCT02644967","phase":"PHASE2","title":"A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Idera Pharmaceuticals, Inc.","startDate":"2015-12","conditions":"Metastatic Melanoma","enrollment":53},{"nctId":"NCT03633110","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine","status":"COMPLETED","sponsor":"Genocea Biosciences, Inc.","startDate":"2018-08-29","conditions":"Cutaneous Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck","enrollment":24},{"nctId":"NCT03937895","phase":"PHASE1, PHASE2","title":"Allogeneic NK Cell (\"SMT-NK\") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"SMT bio Co., Ltd.","startDate":"2019-12-03","conditions":"Biliary Tract Cancer","enrollment":40},{"nctId":"NCT05075122","phase":"PHASE2","title":"Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab","status":"UNKNOWN","sponsor":"Martin-Luther-Universität Halle-Wittenberg","startDate":"2021-08-02","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":75},{"nctId":"NCT05023837","phase":"","title":"Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological Type","status":"COMPLETED","sponsor":"Hunan Province Tumor Hospital","startDate":"2018-03-02","conditions":"Uncommon Pathological Types of Lung Cancer","enrollment":40},{"nctId":"NCT03056599","phase":"PHASE1","title":"Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Presage Biosciences","startDate":"2016-12-15","conditions":"Soft Tissue Sarcoma Adult","enrollment":23},{"nctId":"NCT03139851","phase":"PHASE2","title":"Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2017-06-27","conditions":"Metastatic Breast Cancer","enrollment":36},{"nctId":"NCT02626000","phase":"PHASE1","title":"Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-04-06","conditions":"Carcinoma of the Head and Neck","enrollment":36},{"nctId":"NCT04964479","phase":"PHASE3","title":"A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-08-06","conditions":"Non Small Cell Lung Cancer","enrollment":375},{"nctId":"NCT02501473","phase":"PHASE1, PHASE2","title":"Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)","status":"TERMINATED","sponsor":"Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2016-02-03","conditions":"Follicular Low Grade Non-Hodgkin's Lymphoma","enrollment":52},{"nctId":"NCT04058145","phase":"PHASE2","title":"AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2019-09-30","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT04425226","phase":"NA","title":"Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-08-06","conditions":"Liver Transplant; Complications, Hepatocellular Carcinoma Recurrent","enrollment":192},{"nctId":"NCT01986426","phase":"PHASE1","title":"LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab","status":"COMPLETED","sponsor":"Lytix Biopharma AS","startDate":"2013-11","conditions":"Cancer, Melanoma, Breast Cancer","enrollment":80},{"nctId":"NCT03379441","phase":"PHASE2","title":"Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2018-01-01","conditions":"Non Small Cell Lung Cancer Patients","enrollment":126},{"nctId":"NCT02719015","phase":"PHASE1, PHASE2","title":"Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-03","conditions":"Melanoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pembrolizumab","pembrolizumab"],"phase":"phase_2","status":"active","brandName":"Keytruda Injectable Product","genericName":"Keytruda Injectable Product","companyName":"PDC*line Pharma SAS","companyId":"pdc-line-pharma-sas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PD-1 inhibitor Used for Non-small cell lung cancer, Melanoma, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}